

Aviso de Derechos para emisoras del

FECHA: 24/01/2025

BOLSA MEXICANA DE VALORES, S.A.B DE C.V, INFORMA:

FOLIO DE REFERENCIA DEL EVENTO CORPORATIVO	254508
FOLIO DE REFERENCIA INDEVAL	783788C004
TIPO DE MENSAJE	Replace
COMPLETO / INCOMPLETO	COMPLETE
CONFIRMADO / NO CONFIRMADO	CONFIRMED

CLAVE DE COTIZACIÓN	BNGO
RAZÓN SOCIAL	BIONANO GENOMICS, INC.
SERIE	*
ISIN	US09075F3055
MERCADO PRINCIPAL	NASDAQ

TIPO DE EVENTO	REVERSE STOCK SPLIT/CHANGE IN NOMINAL VALUE
-----------------------	---

MANDATORIO / OPCIONAL / VOLUNTARIO	Mandatory
FECHA EFECTOS	27/01/2025

OPCIÓN	1
TIPO	Security
DEFAULT	true

TRANSACCIÓN	Securities Movement
CREDIT / DEBIT	Debit

Aviso de Derechos para emisoras del



FECHA: 24/01/2025

VALORES A RECIBIR	US09075F3055
TRANSACCIÓN	Securities Movement
CREDIT / DEBIT	Credit

RATIO	NewToOld
	1 / 60
VALORES A RECIBIR	NewIssue
	US09075F4046
DISPOSICIÓN FRACCIONES	CashInLieuOfFraction

NOTAS DEL EVENTO CORPORATIVO

NOTA

24/01/2025

Bionano Genomics, Inc. . Reverse Split Option Symbol. BNGO New Symbol. BNGO1 Date.01 27 2025 Bionano Genomics, Inc. (BNGO) has announced a 1.for.60 reverse stock split. As a result of thereverse stock split, each BNGO Common Share will be converted into the right to receive approximately 0.016667 (New) Bionano Genomics, Inc.Common Shares. The reverse stock split will become effective before the market open on January 27, 2025.Cash will be paid in lieu of fractional shares. Contract Adjustment Effective Date. January 27, 2025 Option Symbol. BNGO changes to BNGO1 Contract Multiplier. 1 Strike Divisor. 1 New Multiplier. 100 (e.g., forpremium or strike dollar extensions 1.00 will equal USD100) New Deliverable Per Contract. 1) 1 (New) Bionano Genomics, Inc. (BNGO) Common Shares 2) Cash in lieu of approximately 0.6667 fractional BNGO Shares Note. Once determined the cash in lieu of fractional share portion of the option deliverable remains fixedand does not vary with price changes of any security. CUSIP. BNGO (New). 09075F404 Pricing Until the cash in lieu amount is determined, theunderlying price for BNGO1 will bedetermined as follows. BNGO1 0.016667 (BNGO)

23/01/2025

Press release January 22, 2025

As a result of the reverse split, each 60 shares of the Company s issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock, par value USD0.0001 per share.

FORM 8-K (1/20/2025)

The Company's stockholders approved a series of alternate amendments to the Company's Amended and Restated Certificate of Incorporation, as amended, to effect, at the option of the Company's Board of Directors, a reverse stock split of the Company's common stock at a ratio between 1-for-25 and 1-for-75, inclusive, with the exact ratio to be determined by the Company's Board of Directors in its sole discretion.

PRE 14A November 25, 2024

You are cordially invited to attend a Special Meeting of Stockholders of Bionano Genomics, Inc., a Delaware corporation, to be held on Wednesday, January 15, 2025, at 10:00 a.m. Pacific Time. The Special Meeting will be held in a virtual meeting format only, via live audio webcast. You will not be able to attend the Special Meeting in person. You will be able to attend and participate in the Special Meeting online by visiting <https://www.virtualshareholdermeeting.com/BNGO2025SM>, where you will be able to listen to the meeting live, submit questions and vote. You will need to have the control number included in the Notice of Internet Availability of Proxy Materials, on your voting instruction form, on your proxy card or on the instructions that accompanied your proxy materials to participate in the virtual Special Meeting. As always, we encourage you to vote your shares prior to the Special Meeting.

You are being asked to vote on the following matter:

2. To approve a series of alternate amendments to the Company's Amended and Restated Certificate of Incorporation, as amended, to effect, at the option of our Board of Directors, a reverse stock split of our common stock at a ratio between 1-for- 25 and 1-for-75,

Aviso de Derechos para emisoras del

FECHA: 24/01/2025

inclusive, as determined by our Board of Directors in its sole discretion and with such reverse stock split to be effected at such time and date, if at all, as determined by our board of directors in its sole discretion. We refer to this as the Reverse Stock Split Proposal or Proposal 2.
21/01/2024

The Companys stockholders approved a series of alternate amendments to the Companys Amended and Restated Certificate of Incorporation, as amended, to effect, at the option of the Companys Board of Directors, a reverse stock split of the ADTX// Companys common stock at a ratio between 1-for-25 and 1-for-75, inclusive, with the exact ratio to be determined by the Companys Board of Directors in its sole discretion. PRE 14A November 25, 2024 You are cordially invited to attend a Special Meeting of Stockholders of Bionano Genomics, Inc., a Delaware corporation, to ADTX// be held on Wednesday, January 15, 2025, at 10:00 a.m. Pacific Time. The Special Meeting will be held in a virtual meeting format only, via live audio webcast. You will not be able to attend the Special Meeting in person. You will be able to attend and participate in the Special Meeting online by visiting [https:// www.virtualshareholdermeeting.com BNGO2025SM](https://www.virtualshareholdermeeting.com/BNGO2025SM), where you will be able to listen to the meeting live, submit questions and vote. You will need to have the control number included in the Notice of Internet Availability of Proxy Materials, on your voting instruction form, on your proxy card or on the instructions that ADTX// accompanied your proxy materials to participate in the virtual Special Meeting. As always, we encourage you to vote your shares prior to the Special Meeting. You are being asked to vote on the following matter:
2. To approve a series of alternate amendments to the Companys Amended and Restated Certificate of Incorporation, as ADTX// amended, to effect, at the option of our Board of Directors, a reverse stock split of our common stock at a ratio between 1-for- 25 and 1-for-75, inclusive, as determined by our Board of Directors in its sole discretion and with such reverse stock split to be effected at such time and date, if at all, as determined by ADTX// our board of directors in its sole discretion. We refer to this as the Reverse Stock Split Proposal or Proposal 2. PACO//GCA External Comment [https:// www.sec.gov Archives edgar data 1411690000114036124047787 ny20038781x1pre14a.htm](https://www.sec.gov/Archives/edgar/data/1411690000114036124047787_ny20038781x1pre14a.htm) TXNR//COL/US TXNR//COI/US